Abstract
Background: We investigated the combination of docetaxeland cisplatin as first-line chemotherapy in patientswith metastatic esophageal cancer. Patients andMethods: 16 chemotherapy-naïve patients with distantmetastases were included in the study (15 male, 1 female;median age: 58.5 years (range 37-69); medianECOG performance status: 1). 11 patients (69%) hadesophageal cancer, and 5 patients (31%) had cancer ofthe gastroesophageal junction. Patients received docetaxel75 mg/m2 and cisplatin 80 mg/m2 on day 1 every3 weeks. A total of 55 chemotherapy cycles was administered.The median number of cycles was 3 (range 1-6).Results: The overall response rate was 31.3%. 4 out of10 patients (40%) with squamous cell carcinoma and1 out of 5 patients (20%) with adenocarcinoma respondedto chemotherapy. The median overall survival was29.6 weeks, and the median progression-free survivalwas 18.6 weeks. Hematological and non-hematologicaltoxicities were moderate (neutropenia WHO grade III/IV:42.9%, alopecia grade II/III: 64.3%, nausea/vomitinggrade II/III: 57.2%, neurotoxicity grade II: 14.3%). Conclusion:The combination of docetaxel and cisplatin is anactive regimen with moderate toxicity in the treatmentof patients with metastatic esophageal cancer. This pilotstudy demonstrates the feasibility of a combinationtreatment containing a taxane and cisplatin in metastaticesophageal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
